Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Avience Biomedicals IPO
Price Band
₹196.0–208.0
Issue Size
₹30.24 Cr
Lot Size
600 shares
Min Investment
₹249,600
2 LOTS MIN
GMP
+₹145.0 (69.71%)
Issue Price
₹208.0
Avience Biomedicals IPO AI Summary
- Avience Biomedicals IPO is listed on NSE SME in the Biotechnology sector.
- Price band: ₹196.0–₹208.0 per share, lot size 600 shares (min. investment ₹249,600, 2 lots minimum).
- Subscription window: 18 Jun–22 Jun 2026, listing on 25 Jun 2026.
- Current GMP is +₹145.0 (69.71%), an estimated listing price of ₹353 — unofficial and can change daily.
Avience Biomedicals Limited is a biotechnology company focused on diagnostic solutions, with a strong product range and a commitment to quality. The IPO has seen significant interest, reflecting investor confidence in its growth potential.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Important Dates
Subscription Status
Overall Subscription
385.32x
| Category | Subscription | Status |
|---|---|---|
| QIB (Institutional) |
196.77x
|
197x 🔥 |
| NII (HNI) |
597.23x
|
597x 🔥 |
| ↳ bNII (>₹10L) |
670.18x
|
670x 🔥 |
| ↳ sNII (<₹10L) |
451.35x
|
451x 🔥 |
| Retail (RII) |
401.36x
|
401x 🔥 |
| Total | 385.32x | 385.32x |
Auto-updated every 5 min · As of 22nd Jun 2026 18:57
Avience Biomedicals IPO Grey Market Premium (GMP) Today
GMP
+₹145.0
GMP %
+69.71%
Est. Listing
₹353.0
Updated: 14 Jul 2026 15:51
About the Company
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry. Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets. The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas. In addition to manufacturing, the Company also act as distributors and traders of medical equipment. The company's manufacturing unit is situated in Noida, Uttar Pradesh. The company offers a comprehensive range of diagnostic solutions, including: Rapid Test Kits: Products like AVISURE Dengue Combo Test, Malaria Rapid Test (Pf/Pv), and AVISURE Syphilis Rapid Test. Biochemistry Analyzers and Reagents: Devices like the BS-240 Fully Auto Analyzer and reagents like AVIENBIO Albumin Kit. Molecular Diagnostics: COVID-19 detection kits, including the COVID-19 Hid RTqPCR ASSAY. Hematology Analyzers: Models like the BC-20s 3-Part Hematology Analyzer. Medical Devices: Oxygen concentrators (Oxy-5 and Oxy-10) and viral transport solutions (VTM). As of December 2024, the company had 65 permanent employees and 33 contractual employees Competitive Strength Strong Industry Experience and Expertise. Avience provides various diagnostic products, including rapid test kits, analyzers, hematology devices, and molecular kits. Strong distribution network across India and is growing its international footprint. Cost-Effective and Affordable Solutions. Stringent quality control processes and complies with ISO standards and regulatory approvals.
Company Financials (₹ Cr)
As of 2026-01-31
| Period Ended | 31 Jan 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 66.07 | 56.52 | 34.65 |
| Total Income | 41.94 | 45.97 | 24.37 |
| Profit After Tax | 5.74 | 7.23 | 2.14 |
| EBITDA | 10.34 | 11.41 | 4.08 |
| NET Worth | 28.52 | 22.78 | 6.21 |
| Reserves and Surplus | 24.49 | 18.75 | 2.93 |
| Total Borrowing | 26.73 | 22.16 | 15.13 |
Key Ratios
EPS
₹17.94
NAV
₹56.50
ROE
50.14%
ROCE
24.84%
RoNW
49.89%
P/B Value
3.68
P/E Ratio
11.59
Market Cap
₹114.09 Cr
PAT Margin
15.86%
Debt/Equity
0.97
Promoters
Dharam Deo Choudhary, Ram Nagina Choudhary, Janardan Pal and Deepa Choudhary
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh 14.05 2 Funding the working capital requirements of the Company 8.25 3 General Corporate Purposes 3.97 4 Public Issue Expenses 3.97 Total 30.24
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total Income was ₹24.37 Cr in the period ending 31 Mar 2024, rising to ₹45.97 Cr by 31 Mar 2025, before declining to ₹41.94 Cr by 31 Jan 2026, though this is a 9-month figure, not a full year, so isn't directly comparable.
Profit Trend
Profit After Tax was ₹2.14 Cr in the period ending 31 Mar 2024, increasing to ₹7.23 Cr by 31 Mar 2025, before decreasing to ₹5.74 Cr by 31 Jan 2026, though this is a 9-month figure, not a full year, so isn't directly comparable.
Grey Market Premium, Explained
The Grey Market Premium (GMP) is an unofficial indicator of the potential listing price of an IPO. It reflects the demand for the shares before they are officially listed on the stock exchange. A higher GMP suggests strong demand, while a lower GMP indicates weaker interest. However, GMP is not guaranteed and can fluctuate until the actual listing.
Subscription Demand
The IPO was well-received, with total bids of 370,597,800 shares against 961,800 shares offered, resulting in an overall subscription of 385.32 times. The QIB category was subscribed 196.77 times, NII (HNI) 597.23 times, and Retail (RII) 401.36 times.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against the company's growth potential, market conditions, and financial health. It's essential to consider the company's business model and the competitive landscape in the biotechnology sector.
Who May Want to Wait
Investors with a low risk tolerance or those seeking stable, income-generating investments may want to avoid IPOs like this, which can be subject to high volatility and uncertainty in the early stages.
IPO Timeline, Explained
The IPO process includes several key dates: the issue opens on 18 June 2026 and closes on 22 June 2026. Allotment of shares will be done on 23 June 2026, and the shares are expected to be listed on the stock exchange on 25 June 2026.
Listing Gains — The Risk
Listing-day gains can be unpredictable and are influenced by market conditions, investor sentiment, and the company's performance. While some IPOs may experience a surge in price on their first day of trading, others may not perform as well. Investors should be prepared for the possibility of both gains and losses.
This evaluation is generated from Avience Biomedicals's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Avience Biomedicals IPO GMP today?
Avience Biomedicals IPO GMP today is +₹145.0 (69.71%), indicating an estimated listing price of ₹353. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Avience Biomedicals IPO?
The price band of Avience Biomedicals IPO is ₹196.0–₹208.0 per share.
When does Avience Biomedicals IPO open and close?
Avience Biomedicals IPO opens on 18 June 2026 and closes on 22 June 2026.
When does Avience Biomedicals IPO list on the stock exchange?
Avience Biomedicals IPO listed on 25 June 2026 at ₹353.0.
What is the lot size for Avience Biomedicals IPO?
The lot size for Avience Biomedicals IPO is 600 shares, requiring a minimum investment of ₹249,600 (2 lots).
What is the price band for the IPO?
The price band for the IPO is ₹196.0 to ₹208.0.
What is the minimum investment required?
The minimum investment required is ₹249,600.
What is the lot size for the IPO?
The lot size for the IPO is 600 shares.
When will the shares be listed?
The shares are expected to be listed on 25 June 2026.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the demand for the shares before they are officially listed.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
18 Jun 2026
Close
22 Jun 2026
Allotment
23 Jun 2026
Listing
25 Jun 2026
Similar IPOs in Biotechnology
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Avience Biomedicals?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.